X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements to motor recovery in individuals with spinal cord injuries (SCI).
Lead Product(s): Oligodendrocyte Progenitor Cell Therapy-1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AST-OPC1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements to motor recovery in individuals with spinal cord injuries (SCI).
Lead Product(s): Oligodendrocyte Progenitor Cell Therapy-1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AST-OPC1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
Lead Product(s): RG6501
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
Lead Product(s): RG6501
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
The novel hypoimmune iPSC line is a targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells.
Lead Product(s): IPSC-derived Cell Ttransplant Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Eterna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
AST-VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells.
Lead Product(s): AST-VAC2
Therapeutic Area: Oncology Product Name: AST-VAC2
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Cancer Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
Under the agreement, Eterna will develop the novel induced hypoimmune pluripotent stem cell (iPSC) lines, which Lineage will evaluate for development into cell transplant therapies and for the treatment of certain CNS disorders and other neurology indications.
Lead Product(s): Hypoimmune Pluripotent Stem Cell
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Eterna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 22, 2023
Details:
In Phase 1/2a clinical trial, RG6501 (OpRegen) demonstrated the potential to slow, stop, or reverse the progression of GA in patients with GA. These results can be maintained beyond one year following a one-time, approximately 30-minute outpatient procedure.
Lead Product(s): RG6501
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
AST-OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements to motor recovery in individuals with acute spinal cord injuries (SCI).
Lead Product(s): Oligodendrocyte Progenitor Cell Therapy-1
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AST-OPC1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
The majority of AEs reported with RG6501, OpRegen (allogeneic retinal pigment epithelial cells) were mild (Cohort 1-3, 87%; Cohort 4, 93%), and the immunosuppressive regimen was well tolerated, for the treatment of geographic atrophy.
Lead Product(s): Allogeneic Retinal Pigment Epithelial Cells
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
